ACM
AQST icon

ADAR1 Capital Management’s Aquestive Therapeutics AQST Stock Holding History

ADAR1 Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$41.5K – 284
2026
Q1 		$41.5K Buy
+10,000
New +$40.6K ﹤0.01% 302

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ADAR1 Capital Management's AQST Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Aquestive Therapeutics (AQST) in Q2 2026, closing a stake of 10,000 shares — an estimated $41.5K sold.

ADAR1 Capital Management first reported a position in AQST in Q1 2026 and held it in 1 quarter. The position peaked at $41.5K in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Aquestive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 10,000 Aquestive Therapeutics shares in Q2 2026, an estimated $41.5K.
  • ADAR1 Capital Management first reported a position in Aquestive Therapeutics in Q1 2026 and held it in 1 quarter.
  • ADAR1 Capital Management's Aquestive Therapeutics position peaked at $41.5K in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.